Elanco Animal Health Incorporated

Elanco Animal Health Incorporated

24.06
EUR
0.00
(0.00%)
-0.26EPS
9.98BMarket Cap
Mar 02Next Earn
Elanco Animal Health Incorporated
GETTEX:5EA
(Gettex)

Recent

price

24.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
8.17
8.18
8.11
9.78
8.32
7.41
9.78
9.03
8.97
8.99
9.5
10.33
Revenue per Share
-0.59
-0.13
-0.87
0.28
0.18
-1.3
-0.99
-0.16
-2.5
0.68
-0.47
-0.29
Basic EPS, GAAP
-0.26
0.13
0.16
1.12
0.07
-0.8
0.59
0.55
0.24
0.77
0.57
0.82
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
19.73
21.28
14.21
14.87
17.96
15.87
15.37
12.63
12.33
13.17
13.26
Book Value per Share
- -
5.14
5.85
-0.73
0.2
-8.76
-8.99
-7.48
-6.83
-4.04
-3.3
-2.4
Tangible Book Value per Share
356
356
356
314
369
441
487
488
492
494
496
498
Basic Weighted Avg Shares
2,909
2,914
2,889
3,067
3,071
3,271
4,764
4,411
4,417
4,439
4,715
5,148
Sales/Revenue/Turnover
0.19
9.72
4.93
10.23
12.08
-2.51
6.38
8.71
7.38
5.65
5.34
7.58
Operating Margin (%)
237
254
318
296
314
517
716
682
694
662
680
694
Depreciation Expense
-211
-48
-311
87
68
-574
-483
-78
-1,231
338
-232
-147
Net Income, GAAP
- -
- -
- -
24.19
12.82
- -
- -
- -
- -
30.74
- -
- -
Effective Tax Rate (%)
-7.25
-1.64
-10.75
2.82
2.21
-17.55
-10.14
-1.77
-27.87
7.61
-4.92
-2.86
Profit Margin (%)
- -
1,329
1,481
1,534
1,555
1,340
1,627
1,577
2,166
1,900
1,861
1,939
Working Capital
- -
- -
- -
2,443
2,331
5,572
6,025
5,448
5,736
4,277
3,943
3,633
LT Debt
- -
7,028
7,780
5,198
5,547
8,476
7,508
7,289
6,223
6,096
6,547
6,628
Total Equity
- -
- -
- -
1.82
2.07
- -
- -
- -
- -
4.59
- -
- -
Return on Invested Capital (%)
- -
- -
- -
1.41
1.76
- -
- -
- -
- -
4.47
- -
- -
Return on Capital (%)
- -
- -
-4.2
1.33
1.27
-8.19
-6.04
-1.05
-18.22
5.49
-3.67
-2.2
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
73
73
74
LT Borrowings
3,918
3,845
3,633
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
499
500
500
Market Capitalization
11,987
12,336
11,316

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
3,584
3,797
3,726
Cash, Cash Equivalents & STI
428
530
465
Accounts Receivable, Net
1,084
1,077
992
Inventories
1,717
1,769
1,818
Total Current Liabilities
1,662
1,852
1,787
Payables & Accruals
372
427
416
ST Debt
73
73
74
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-4.72%
7.4%
Free Cash Flow
-114.61%
-8.87%
-25.26%
Net Income, GAAP
46.04%
216.48%
-168.64%
Sales/Revenue/Turnover
5.72%
9.02%
6.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,205
1,184
1,030
1,020
4,439
2025
1,193
1,241
1,137
1,144
4,715
2026
1,371
1,368
1,265
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
-0.1
0.74
-0.02
0.68
2025
0.14
0.02
-0.07
-0.56
-0.47
2026
0.11
0.11
0.04
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health that develops, manufactures, and markets innovative products and services to prevent and treat diseases in farm animals and pets. The company offers a comprehensive portfolio including parasiticides such as Credelio Quattro, Zenrelia, Advantage Family, and Seresto for pets; productivity enhancers like Experior and AdTab for cattle; vaccines, antibiotics, and feed additives for poultry and swine; and knowledge services providing data-driven insights to veterinarians, farmers, and pet owners worldwide. Elanco operates in over 100 countries with a focus on pet health and livestock sustainability segments, targeting veterinarians, farmers, pet owners, and food producers. Founded in 1954 as a division of Eli Lilly and Company and headquartered in Indianapolis, Indiana, Elanco spun off as an independent public company in 2018 and maintains manufacturing, research, and commercial operations globally. Recent strategic changes include the completed divestiture of its aqua business to Merck Animal Health for $1.3 billion in July 2024, enabling focus on core pet and farm animal growth areas; refinancing of a $2.1 billion Term Loan B facility in 2025 to extend maturities to 2032 and reduce interest costs; monetization of certain lotilaner U.S. royalties for $295 million in May 2025; and the opening of a new global headquarters in downtown Indianapolis. In third quarter 2025 results, Elanco reported organic constant currency revenue growth of 9%, driven by strong performances from Credelio Quattro (reaching $100 million in net sales within eight months), Zenrelia (global sales nearly doubling quarter-over-quarter with launches in the EU, Great Britain, and Australia), Experior (up 70% year-over-year), and AdTab (up over 25% year-over-year), while raising full-year 2025 guidance for revenue, innovation revenue, adjusted EBITDA, and adjusted EPS alongside an improved year-end net leverage ratio target of 3.7x to 3.8x.

Company News

  • Elanco Animal Health Incorporated (ELAN) Presents at 2026 UBS Global Healthcare Conference Transcript

  • Elanco Animal Health: 3 Key Takeaways for Long-Term Investors

  • Elanco Animal Health Q3 Earnings Call Highlights

  • Elanco Animal Health Incorporated (ELAN) Q3 2026 Earnings Call Transcript

  • Elanco Animal Health Sees Strong Momentum Heading Into 2027

  • Elanco Animal Health (ELAN) Reports Q3 Earnings: What Key Metrics Have to Say

  • Elanco Animal Health Incorporated (ELAN) Q3 Earnings and Revenues Surpass Estimates

  • Elanco Animal Health Reports Third Quarter 2026 Results

  • October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority

  • Moderna, Humana and Elanco Earnings Previews: What Investors Should Watch

  • Elanco to Participate in UBS Global Healthcare Conference

  • Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

  • Elanco Animal Health Appoints Jamie Preston as Chief People Officer

  • Here Are Tuesday’s Top Wall Street Analyst Research Calls: Akamai Technolgies, Apple, Blackrock, Ford Motor, Healthcare Realty Trust, Noble, Sunoco LP, Venture Global, Western Midstream Partners, Zoetis, and More

  • Elanco Animal Health (NYSE:ELAN) Insider Timothy Bettington Sells 4,350 Shares of Company Stock

  • Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?

  • Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground

  • State Street Corp Has $395.31 Million Holdings in Elanco Animal Health Incorporated $ELAN

  • Elanco Animal Health Incorporated (ELAN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

  • Analyzing Amarin (NASDAQ:AMRN) & Elanco Animal Health (NYSE:ELAN)